Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinomaReportar como inadecuado

Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal Title:

British Journal of Cancer


Volume 113, Number 1


Cancer Research UK | 2015-06-30, Pages 64-68

Type of Work:

Article | Final Publisher PDF

Abstract: Background: Outcomes for ampullary adenocarcinomas are heterogeneous, and numerous methods of categorisation exist. A histomolecular phenotype based on histology, caudal-type homeodomain transcription factor 2 CDX2 staining and Mucin 1 MUC1 staining has recently been tested and validated in two cohorts. We attempt to validate this classification in a large patient population.Methods: Tissue samples from 163 patients with resected ampullary adenocarcinoma were classified based on histology and immunohistochemical expression of CDX2 and MUC1. A pancreaticobiliary histomolecular classification PB was defined as a sample with pancreaticobiliary histology, positive MUC1 and negative CDX2 expression.Results: There were 82 deaths; median follow-up of 32.4 months; and median overall survival of 87.7 95% CI 42.9–109.5 months. PB comprised 28.2% of the cases. Factors associated with overall survival were histological subtype P=0.0340; T1-2 vs T3-4 P=0.001; perineural P<0.0001 and lymphovascular P=0.0203 invasion; and histomolecular intestinal histomolecular phenotype INT vs PB phenotype 106.4 vs 21.2 months, P<0.0001. Neither MUC1 nor CDX2 was statistically significant, although MUC1 positivity defined as ⩾10% staining was significant P=0.0023. In multivariate analysis, age HR 1.03, PB phenotype HR 2.26 and perineural invasion PNI; HR 2.26 were associated with poor survival.Conclusions: The prognostic ability of histomolecular phenotype has been validated in an independent cohort of ampullary adenocarcinoma patients.

Subjects: Health Sciences, Oncology - Health Sciences, Pathology - Research Funding: This work was supported by The Kavanagh Family Foundation.

Keywords: Science and Technology - Life Sciences and Biomedicine - Oncology - ampullary adenocarcinoma - MUC1 - CDX2 - histomolecular phenotype - prognostic - PERIAMPULLARY ADENOCARCINOMA - ADJUVANT CHEMOTHERAPY - GENE-EXPRESSION - INTESTINAL-TYPE - VATER - CARCINOMA - CANCER - PROGNOSIS - SURVIVAL - IMMUNOHISTOCHEMISTRY -

Autor: A Schueneman, M Goggins, J Ensor, B Saka, N Neishaboori, S Lee, A Maitra, G Varadhachary, N Rezaee, C Wolfgang, Nazmi Adsay, H Wa



Documentos relacionados